RegeneRx Biopharmaceuticals Company Description
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tβ4) for tissue protection, repair, and regeneration.
The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis.
It has strategic partnerships with Lee’s Pharmaceutical Group for the development and marketing of Tβ4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 for dermal wound healing.
The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in December 2000.
RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
| Country | United States |
| Founded | 1982 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | J. Finkelstein |
Contact Details
Address: 15245 Shady Grove Road Rockville, Maryland 20850 United States | |
| Phone | 301 208 9191 |
| Website | regenerx.com |
Stock Details
| Ticker Symbol | RGRX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US75886X1081 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| J. J. Finkelstein | President, Chief Executive Officer and Director |
| Dr. Allan L. Goldstein Ph.D. | Founder, Chairman, Chief Scientific Officer and Chairman of Scientific Advisor Board |